FIELD: medicine, pharmaceutics.
SUBSTANCE: invention relates to acylated analogue of insulin, containing lysine residue, which is connected with C-end of amino acid residue A21, where acyl group, including alkylene glycol group, is bound to lysine residue in position A22.
EFFECT: claimed compounds can be introduced in pulmonary way.
7 cl, 51 ex
Title | Year | Author | Number |
---|---|---|---|
ACYLATED INSULIN ANALOGUES STABILISED WITH RESPECT TO PROTEASES | 2009 |
|
RU2571857C2 |
INSULIN DERIVATIVES CONTAINING ADDITIONAL DISULFIDE BONDS | 2011 |
|
RU2598273C2 |
NOVEL INSULIN DERIVATIVES AND USE THEREOF | 2015 |
|
RU2684456C2 |
PHARMACEUTICAL COMPOSITIONS CONTAINING INSULIN | 2017 |
|
RU2758367C2 |
NOVEL DERIVATIVE OF INSULIN ANALOGUE | 2014 |
|
RU2673185C2 |
PROTEASE-RESISTANT INSULIN ANALOGUES | 2007 |
|
RU2524150C2 |
POLYPEPTIDES | 2012 |
|
RU2669999C2 |
NOVEL GLUCAGON ANALOGUES | 2012 |
|
RU2610175C2 |
NOVEL GLUCAGON ANALOGUES | 2011 |
|
RU2559320C2 |
INSULIN PURIFICATION | 2012 |
|
RU2603752C2 |
Authors
Dates
2014-04-27—Published
2008-08-15—Filed